Choosing a CDMO for the Long Haul: How to Tell a Real Track Record From a Slogan
Most decisions in a biologics program can be revisited. The choice of a manufacturing partner usually cannot. By the time a molecule moves from first GMP batch toward commercial supply, the relationship with its CDMO has often outlasted the strategy, the funding round, and sometimes the team that signed the contract.
That is the starting point Dr. Patrick Meyer, Global Head of Business Development at Rentschler Biopharma, takes in a recent video interview on CDMO selection. His framing is deliberately unromantic about procurement and quite romantic about everything else:
"It's almost a bit like a marriage. So making that decision for the right partner in the very beginning of your project life cycle is very, very important."
Performance over pricing
The most consequential trade-off in CDMO selection is also the easiest one to get wrong, because only one side of it appears on a quote. Price is legible immediately. Performance reveals itself over years.
Meyer's position is that the long-term view should dominate: a project brought to a CDMO "will run years," which means the relevant question is not what a batch costs today but whether the partner can still deliver against that commitment several development stages from now. Selecting on unit price optimizes for the first campaign. Selecting on proven performance optimizes for the filing.
What a client should be able to expect
Asked what a biotech should demand from a CDMO, Meyer's answer is notably operational rather than aspirational - full transparency, timelines that can actually be planned against, and reliability on commitments. He summarizes the standard bluntly: no surprises, and in the end, no headaches.
He notes this is a description clients have applied to Rentschler in the past - and treats it less as a compliment than as the baseline obligation. The underlying point is that a CDMO relationship fails in predictable ways: schedule slippage discovered late, technical problems disclosed after they become expensive, commitments quietly renegotiated. Transparency is the control mechanism for all three.
Alongside it sits demonstrated technical command. A client needs to see that the CDMO has the situation under control - the in-house expertise, the subject-matter specialists assigned to the project, and a supply chain that is itself proven rather than assumed.
Getting past the marketing slogan
The most useful part of the interview is its answer to a practical problem: every CDMO claims reliability and expertise, so how does a sponsor distinguish a real capability from a well-designed website?
Meyer's answer is to insist on evidence, particularly evidence of commercial progression - and he puts Rentschler's own numbers on the table:
- Roughly 180 molecules handled to date
- About a quarter progressed into late-stage commercial development
- Nine programs taken with clients through to commercialization, with another nine expected in the near term
The reason this specific evidence matters is structural. Plenty of organizations can run an early-stage batch. Far fewer have repeatedly navigated the transition into late-stage and commercial manufacturing, where process characterization, validation, and regulatory scrutiny intensify. As Meyer puts it, a sponsor should want to know "what kind of a partner you're buying into" - beyond the slogan.
The same logic applies to molecular complexity. Difficult formats are, in his words, not something everyone can do "just out of the get-go." A track record with complex molecules is the only credible proof that a CDMO can handle one.
Continuity across the molecule's lifetime
There is a second reason track record matters, and it is about staying power rather than skill.
A program spans years. The ideal is a single partner across the entire arc - from early development through to commercialization - because every transfer between organizations costs time, risks comparability, and re-opens questions that were already settled. Meyer's observation is that relatively few CDMOs can genuinely offer that assurance across a molecule's full lifetime.
That reframes the selection question. Instead of can this partner run my next campaign, the question becomes will this partner still be the right one when I am filing - a question about a company's stability and depth, not just its equipment list.
The part clients discover later
Meyer draws a distinction between what the market already knows about Rentschler and what tends to surprise new clients.
The known part is technical: process technologies such as perfusion and fed-batch are, in his words, "a given" - the company's established reputation. The less-anticipated part is how the partnership actually feels day to day. Rentschler's position as a mid-size CDMO is presented here as a deliberate structural advantage rather than a limitation:
"We have that luxury that we don't work with 50 or hundreds of clients at the same time. So every client that comes to Rentschler can expect that their baby, their product, is in good hands."
Working "on eye level," in his phrase, is a function of portfolio size. A CDMO running hundreds of concurrent programs allocates attention by necessity. One running fewer can treat each product as consequential - which is precisely what a sponsor with a single lead asset needs.
Stability as infrastructure
The interview closes on the least fashionable and perhaps most decisive attribute: institutional durability. Rentschler is family-owned and more than 150 years old. In a sector where CDMOs are regularly acquired, restructured, or refocused mid-program, ownership stability is not a heritage detail - it is a risk control.
If the partnership is expected to last the lifetime of a molecule, then the partner's own expected lifetime is a legitimate diligence question.
The short version
For teams currently running a CDMO selection process, the interview suggests a compact checklist:
- Weigh performance above price. The quote covers one campaign; the relationship covers the program.
- Demand planable timelines and full transparency. No surprises is a measurable standard, not a sentiment.
- Ask for commercial evidence, not capability claims. How many programs have actually reached commercialization?
- Check experience with molecules like yours. Complexity is proven, not asserted.
- Assess whether the partner can go the full distance - technically and as an institution.
Watch the full conversation: Choosing the Right CDMO for Long-Term Stability with Dr. Patrick Meyer, Global Head of Business Development, Rentschler Biopharma.
Considering a partner for your next program? Talk to our Business Development team.
